2008;9:694 9. 113. Bayes-Genis A, Lopez L, Zapico E, et al. NT-ProBNP reduction percentage during admission for acutely decompensated heart failure predicts long- term cardiovascular mortality. J Card Fail. 2005;11:S3 8. 114. Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M, et al. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail. 2002;4:331 6. 115. Dieplinger B, Gegenhuber A, Kaar G, et al. Prognostic value of estab- lished and novel biomarkers in patients with shortness of breath attend- ing an emergency department. Clin Biochem. 2010;43:714 9. 116. Januzzi JL Jr, Peacock WF, Maisel AS, et al. Measurement of the inter- leukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol. 2007;50:607 13. 117. Manzano-Fernandez S, Mueller T, Pascual-Figal D, et al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol. 2011;107:259 67. 118. Rehman SU, Mueller T, Januzzi JL Jr. Characteristics of the novel interleu- kin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol. 2008;52:1458 65. 119. Shah RV, Chen-Tournoux AA, Picard MH, et al. Galectin-3, cardiac struc- ture and function, and long-term mortality in patients with acutely de- compensated heart failure. Eur J Heart Fail. 2010;12:826 32. 120. de Boer RA, Lok DJ, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43:60 8. 121. Lok DJ, van der Meer P, de la Porte PW, et al. Prognostic value of galec- tin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. 